Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508).

Argiris A, Lee JW, Stevenson J, Sulecki MG, Hugec V, Choong NW, Saltzman JN, Song W, Hansen RM, Evans TL, Ramalingam SS, Schiller JH.

Ann Oncol. 2017 Dec 1;28(12):3037-3043. doi: 10.1093/annonc/mdx534.

PMID:
28950351
2.

Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia.

Brinkerhoff BT, Choong NW, Treisman JS, Poetker DM.

Am J Otolaryngol. 2012 May-Jun;33(3):349-51. doi: 10.1016/j.amjoto.2011.07.012. Epub 2011 Sep 13.

PMID:
21917353
3.

Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia.

Brinkerhoff BT, Poetker DM, Choong NW.

N Engl J Med. 2011 Feb 17;364(7):688-9. doi: 10.1056/NEJMc1012774. No abstract available.

4.

Stereotactic radiosurgery for the management of brain metastases.

Choong NW, Gore E.

N Engl J Med. 2010 Aug 5;363(6):592; author reply 592-3. doi: 10.1056/NEJMc1005003. No abstract available.

PMID:
20836240
5.

Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.

Choong NW, Mauer AM, Haraf DC, Ferguson MK, Sandler AB, Kesler KA, Fishkin PA, Ansari RH, Wade J 3rd, Krauss SA, Sciortino DF, Posner MC, Kocherginsky M, Hoffman PC, Szeto L, Vokes EE.

Med Oncol. 2011 Dec;28 Suppl 1:S152-61. doi: 10.1007/s12032-010-9658-1. Epub 2010 Aug 21.

PMID:
20730572
6.

EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.

Faoro L, Singleton PA, Cervantes GM, Lennon FE, Choong NW, Kanteti R, Ferguson BD, Husain AN, Tretiakova MS, Ramnath N, Vokes EE, Salgia R.

J Biol Chem. 2010 Jun 11;285(24):18575-85. doi: 10.1074/jbc.M109.075085. Epub 2010 Apr 1.

7.

Phase II study of sunitinib malate in head and neck squamous cell carcinoma.

Choong NW, Kozloff M, Taber D, Hu HS, Wade J 3rd, Ivy P, Karrison TG, Dekker A, Vokes EE, Cohen EE.

Invest New Drugs. 2010 Oct;28(5):677-83. doi: 10.1007/s10637-009-9296-7. Epub 2009 Aug 4.

PMID:
19649772
8.

Complete and durable response of choroid metastasis from non-small cell lung cancer with systemic bevacizumab and chemotherapy.

George B, Wirostko WJ, Connor TB, Choong NW.

J Thorac Oncol. 2009 May;4(5):661-2. doi: 10.1097/JTO.0b013e31819c9a73.

9.

Recurrent laryngeal nerve palsy on integrated positron emission tomography-computed tomography.

Choong NW, Hellman RS.

J Thorac Oncol. 2008 Oct;3(10):1172. doi: 10.1097/JTO.0b013e318186a866. No abstract available.

10.

Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.

Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T, Olopade OI, Salgia R, Vokes EE.

J Thorac Oncol. 2008 Sep;3(9):1003-11. doi: 10.1097/JTO.0b013e31818396a4.

11.

Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.

Choong NW, Vokes EE, Haraf DJ, Tothy PK, Ferguson MK, Kasza K, Rudin CM, Hoffman PC, Krauss SA, Szeto L, Mauer AM.

J Thorac Oncol. 2008 Jan;3(1):59-67. doi: 10.1097/JTO.0b013e31815e8566.

12.

Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer.

Choong NW, Mauer AM, Hoffman PC, Rudin CM, Winegarden JD 3rd, Villano JL, Kozloff M, Wade JL 3rd, Sciortino DF, Szeto L, Vokes EE.

J Thorac Oncol. 2006 Mar;1(3):245-51.

13.

Key signaling pathways and targets in lung cancer therapy.

Choong NW, Salgia R, Vokes EE.

Clin Lung Cancer. 2007 Feb;8 Suppl 2:S52-60. Review.

PMID:
17382025
14.

Forthcoming receptor tyrosine kinase inhibitors.

Choong NW, Cohen EE.

Expert Opin Ther Targets. 2006 Dec;10(6):793-7.

PMID:
17105367
15.

Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.

Choong NW, Dietrich S, Seiwert TY, Tretiakova MS, Nallasura V, Davies GC, Lipkowitz S, Husain AN, Salgia R, Ma PC.

Nat Clin Pract Oncol. 2006 Jan;3(1):50-7; quiz 1 p following 57.

PMID:
16407879
16.

Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer.

Choong NW, Vokes EE.

Clin Lung Cancer. 2005 Dec;7 Suppl 3:S98-104. Review.

PMID:
16384544
17.

Epidermal growth factor receptor directed therapy in head and neck cancer.

Choong NW, Cohen EE.

Crit Rev Oncol Hematol. 2006 Jan;57(1):25-43. Epub 2005 Oct 3. Review.

PMID:
16207530
18.

Therapeutic targeting of receptor tyrosine kinases in lung cancer.

Choong NW, Ma PC, Salgia R.

Expert Opin Ther Targets. 2005 Jun;9(3):533-59. Review.

PMID:
15948672
19.

Small cell carcinoma of the urinary bladder. The Mayo Clinic experience.

Choong NW, Quevedo JF, Kaur JS.

Cancer. 2005 Mar 15;103(6):1172-8.

20.

Bilateral carotid body paraganglioma.

Choong NW, Miles JM.

Mayo Clin Proc. 2004 May;79(5):681. No abstract available.

PMID:
15132413
21.

Intramural gastric abscess: case history and review.

Choong NW, Levy MJ, Rajan E, Kolars JC.

Gastrointest Endosc. 2003 Oct;58(4):627-9. No abstract available.

PMID:
14560756
22.

28-year-old man with recurrent fever.

Nguyen AQ, Choong NW, Spittell PC.

Mayo Clin Proc. 2003 Jul;78(7):897-900. No abstract available.

PMID:
12839086
23.

67-year-old man with hepatitis C infection and abdominal distention.

Choong NW, Asfandiyar S, Roberts LR.

Mayo Clin Proc. 2003 Feb;78(2):217-20. No abstract available.

PMID:
12583532

Supplemental Content

Loading ...
Support Center